Type 2 Diabetes Screening and Treatment Guideline

Interim Update May 2023 ........................................................................................................................................... 2
Past Updates ............................................................................................................................................................... 2
Prevention ................................................................................................................................................................. 2
Screening and Tests .................................................................................................................................................. 3
Diagnosis .................................................................................................................................................................... 3
Treatment .................................................................................................................................................................. 4
  Risk-reduction goals ............................................................................................................................................. 4
  Lifestyle modifications and non-pharmacologic options ..................................................................................... 5
  Bariatric surgery .................................................................................................................................................... 6
  Pharmacologic options for glucose control ........................................................................................................ 6
  Type 2 diabetes treatment algorithm .................................................................................................................. 10
  Type 2 diabetes treatment: when to consider glargine or U-500 insulin ......................................................... 11
  Additional pharmacologic options to consider in consultation with Diabetes Team ...................................... 12
  Pharmacologic options that are not recommended .......................................................................................... 13
Chronic Disease Management (CDM) Support ...................................................................................................... 14
Follow-up and Monitoring ..................................................................................................................................... 15
  Self blood glucose monitoring ............................................................................................................................ 15
  Periodic monitoring of medication effectiveness and adverse effects .............................................................. 16
  Periodic monitoring of conditions and complications .................................................................................... 17
  Recommended immunizations ............................................................................................................................ 18
Comorbidities ........................................................................................................................................................... 18
Evidence Summary .................................................................................................................................................. 19
References ................................................................................................................................................................. 22
Guideline Development Process and Team ............................................................................................................. 25

Last guideline approval: March 2021

Guidelines are systematically developed statements to assist patients and providers in choosing appropriate health care for specific clinical conditions. While guidelines are useful aids to assist providers in determining appropriate practices for many patients with specific clinical problems or prevention issues, guidelines are not meant to replace the clinical judgment of the individual provider or establish a standard of care. The recommendations contained in the guidelines may not be appropriate for use in all circumstances. The inclusion of a recommendation in a guideline does not imply coverage. A decision to adopt any particular recommendation must be made by the provider in light of the circumstances presented by the individual patient.
Interim Update May 2023
The Type 2 Diabetes Guideline has been updated to reflect the following changes:

- The Prior Authorization (PA) requirement for empagliflozin has been removed.
- The Type 2 Diabetes Treatment algorithm has been updated to clarify that the threshold eGFR for starting SGLT-2 inhibitors is 20 mL/min.
- The threshold eGFR for starting metformin remains at 45 mL/min.
- Monitoring recommendations for patients on SGLT-2 inhibitors and GLP-1 receptor agonists are now included.
- Contraindications and sick day recommendations for SGLT-2 inhibitors have been added.

A full review of the KPWA Type 2 Diabetes Guideline is scheduled for later in 2023, and additional changes to care recommendations are anticipated.

Past Updates

Interim update December 2022
The type 2 diabetes treatment algorithm has been updated to reflect the following changes:

- **Metformin** remains the appropriate first-line agent for glucose lowering in type 2 diabetes.
- Due to the risk of hypoglycemia, **insulin** is now recommended only for those patients with type 2 diabetes who require an HbA1c reduction of ≥ 2%.
- For patients with type 2 diabetes who are close to or at goal (requiring an HbA1c reduction of < 2%):
  - **SGLT-2 inhibitors** are now considered second-line add-on therapy in:
    - Those with established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure (HF), and
    - Those aged ≥ 55 years plus at least two of the following: hypertension (on medication), BMI ≥ 30, dyslipidemia.
  - This recommendation is based on strong evidence that SGLT-2 inhibitors improve cardiovascular disease, heart failure, and renal disease outcomes.
  - **GLP-1 receptor agonists** are now considered third-line add-on therapy in those who have a) established ASCVD, b) contraindication, intolerance, or failure of SGLT-2 inhibitors, and c) tried metformin. This recommendation is based on moderate evidence that GLP-1 receptor agonists improve cardiovascular outcomes.

Interim update September 2021

Annual monitoring of estimated glomerular filtration rate (eGFR) is now recommended for all patients with diabetes to be in compliance with the HEDIS® Kidney Health Evaluation for Patients with Diabetes (KED) measure. Previously, microalbumin/creatinine ratio was the only recommended lab test for monitoring kidney health.

It is now recommended that **diabetes screening for patients with overweight/obesity start at age 35**, to be in alignment with new 2021 U.S. Preventive Services Task Force recommendations. Previously, screening was recommended for such patients starting at age 45.

Changes as of March 2021
Following scheduled review, the KP Washington Type 2 Diabetes Guideline team determined that there were no outstanding evidence gaps and re-approved the guideline with only minor changes to content. The KPWA guideline is in alignment with current KP National clinical guidance.

Prevention
Studies have shown that increasing physical activity and eating a healthy diet can significantly delay the onset of type 2 diabetes, including for patients diagnosed with impaired glucose tolerance. Studies have also shown that the use of metformin can delay the diagnosis of diabetes for patients with impaired glucose tolerance, but there is no evidence that metformin or any other medication leads to long-term better clinical outcomes prior to diagnosis of diabetes.
Screening and Tests
The U.S. Preventive Services Task Force (2021) recommends screening patients who are at increased risk for diabetes.

Risk factors for type 2 diabetes include:
- Age of 35 years or older with overweight or obesity
- Consider screening earlier in patients with certain racial/ethnic backgrounds, including African American, American Indian/Alaska Native, Asian American, Hispanic/Latino, and Native Hawaiian/Pacific Islander.
- It is reasonable to have a higher clinical index of suspicion in adults with multiple risk factors (such as first-degree relative with diabetes, PCOS) and to use clinical judgment or shared decision-making about screening for type 2 diabetes.

If the decision is to screen, consider a frequency of every 3 years using either fasting plasma glucose or HbA1c.

Adults at high risk for atherosclerotic cardiovascular disease (see the KPWA guidelines for primary and secondary prevention of ASCVD) should be considered for screening. While ASCVD itself is not a risk factor for type 2 diabetes, type 2 diabetes is a serious complicating comorbidity in patients with ASCVD. If they elect screening, these patients should be screened every 3 years using either fasting plasma glucose or HbA1c.

Annual screening is recommended for women with a history of gestational diabetes (using HbA1c) and for men and women with impaired fasting blood glucose (using either fasting plasma glucose or HbA1c).

Diagnosis
Diagnosis for an asymptomatic patient requires two abnormal test results, which can be from the same test performed on different days, or from different tests performed on either the same day or different days. If only one test comes back abnormal, repeat the abnormal test on a different day. An abnormal result on the repeated test is diagnostic for diabetes.

Diagnosis for a patient with classic symptoms of hyperglycemia (i.e., polyuria, polydipsia, weight loss) can be made with a single random plasma glucose result of 200 mg/dL or higher. A repeat measurement is not needed.

<table>
<thead>
<tr>
<th>Test</th>
<th>Results</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c</td>
<td>6.5% or higher</td>
<td>Diabetes</td>
</tr>
<tr>
<td></td>
<td>5.7–6.4%</td>
<td>Impaired glucose tolerance 1</td>
</tr>
<tr>
<td></td>
<td>Lower than 5.7%</td>
<td>Normal</td>
</tr>
<tr>
<td>Random plasma glucose</td>
<td>200 mg/dL or higher</td>
<td>Diabetes</td>
</tr>
<tr>
<td></td>
<td>140–199 mg/dL</td>
<td>Impaired glucose tolerance 1</td>
</tr>
<tr>
<td></td>
<td>Lower than 140 mg/dL</td>
<td>Normal</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>126 mg/dL or higher</td>
<td>Diabetes</td>
</tr>
<tr>
<td></td>
<td>100–125 mg/dL</td>
<td>Impaired glucose tolerance 1</td>
</tr>
<tr>
<td></td>
<td>Lower than 100 mg/dL</td>
<td>Normal</td>
</tr>
</tbody>
</table>

1 Impaired glucose tolerance (IGT) is similar to impaired fasting glucose (IFG) but is diagnosed with a confirmed oral glucose tolerance test (OGTT). Both IGT and IFG are risk factors for future diabetes and for cardiovascular disease. They are sometimes jointly referred to as pre-diabetes. This guideline recommends avoiding the term pre-diabetes because not all patients with IGT and/or IFG will develop diabetes.
Patients with type 2 diabetes most commonly present as overweight and hyperglycemic, with gradual onset of symptoms such as fatigue, blurred vision, polydipsia, and polyuria.

Consider islet cell antibody (ICA) with reflex to glutamic acid decarboxylase antibody (GADA) testing for differential diagnosis in the following patient populations:
- Children and teenagers to distinguish early type 1 diabetes from type 2 diabetes.
- Adults who are not overweight and who are not responding well to oral hypoglycemic and lifestyle (diet/exercise) modification.

The following laboratory tests are not recommended:
- Fasting C-peptide is not recommended because the test cannot distinguish well between people without diabetes and those with impaired endogenous insulin secretion. C-peptide is released from the pancreas in equimolar amounts to endogenous insulin. Because the amount of endogenous insulin secreted is dependent on a patient's blood glucose level, low or undetectable C-peptide levels may indicate either an inability to produce insulin or an absence of insulin secretion due to low blood sugar levels. In the latter case, a person without diabetes would not secrete much C-peptide and would have an abnormal test result.
- Plasma insulin is not recommended as it does not add any additional useful information.

Treatment
Primary Care clinicians manage diabetes care—including overall plans of care and annual reviews of care—for all patients with diabetes, with help as needed from the Diabetes Team (use REF CDM CLINICAL NURSING SERVICES).

Risk-reduction goals
Cardiac risk reduction is the most important management issue for patients with diabetes.

<table>
<thead>
<tr>
<th>Table 2. Selected cardiac risk factors and goals for risk reduction for patients with diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factor</td>
</tr>
<tr>
<td>Blood pressure</td>
</tr>
<tr>
<td>LDL cholesterol</td>
</tr>
<tr>
<td>HbA1c</td>
</tr>
<tr>
<td>Fasting blood glucose</td>
</tr>
</tbody>
</table>

1 Use clinical judgment to determine if a target lower than 7.0% is appropriate for an individual patient. It can be challenging to push a patient’s HbA1c levels from just above 7.0% to below 7.0%. There are potential benefits (decreased nonfatal myocardial infarction) and potential harms (hypoglycemia, weight gain, and possible increase in all-cause and cardiovascular-cause mortality) of intensive glucose therapy, especially in patients with known cardiovascular disease. For frail elderly patients, a target HbA1c of 7.0–9.0% is reasonable.
Lifestyle modifications and non-pharmacologic options

For information on nursing management of patients with type 2 diabetes, see Diabetes Care at KPWA (SharePoint site).

Diet and physical activity

There is some evidence that intensive programs of lifestyle interventions targeting patients with impaired fasting blood glucose reduce the incidence of type 2 diabetes. Lifestyle interventions include dietary and physical activity counseling.

All patients should strive to:

- Make smart choices from every food group to meet their caloric needs.
- Get the most and best nutrition from the calories consumed.
- Find a balance between food intake and physical activity.
- Get at least 30 minutes of moderate-intensity physical activity on most days.

For personalized eating plans and interactive tools to help patients plan and assess food choices, see the U.S. Department of Agriculture's Choose My Plate website.

A low-carbohydrate Mediterranean diet rich in fruits, vegetables, nuts, whole grains, legumes, fish, and healthy fats from plant and fish sources is recommended. There is evidence to suggest that this type of diet improves diabetes-related health outcomes more than low-fat diets in patients with type 2 diabetes. Use the SmartPhrase avsmediterraneandiet.

For patients who have been inactive, recommend slowly working up to at least 30 minutes of moderate physical activity per day. If they are unable to be active for 30 minutes at one time, suggest accumulating activity in 10- to 15-minute sessions throughout the day.

Foot care

For patients at very high risk or increased risk of developing foot ulcers, recommend daily foot care. The pamphlet “Living Well with Diabetes: Foot care for people with diabetes” is available online and can be ordered from the Resource Line (#63).

Foot-ulcer risk definitions:

- Patients at very high risk are those with a previous foot ulcer, amputation, or major foot deformity (claw/hammer toes, bony prominence, or Charcot deformity).
- Patients at increased risk are those who are insensate to 5.07 monofilament at any site on either foot or who have bunions, excessive corns, or callus.
- Patients at average risk are those with none of the aforementioned complications.

Encourage patients to check their feet regularly. If the patient or a family member cannot perform the patient’s foot care, encourage the patient to find someone who can provide assistance.

Sick-day management

Patients experiencing acute illnesses need to be extra vigilant about blood glucose monitoring and control. The following information and help are available:

- Patients at risk for dehydration should stop both SGLT inhibitors and metformin.
- The pamphlet “Living Well with Type 2 Diabetes: Taking care of yourself when you’re sick” is available online and can be ordered (#338) from the Resource Line; also available in Spanish. Or use SmartPhrase chronicdiseasedmtype2sickdayplan.
- Pharmacy staff can help with selecting sugar-free cold medicines and cough syrups.

Weight management

The risk of serious health conditions—such as high blood pressure, heart disease, arthritis, and stroke, as well as diabetes—increases with body mass index (BMI) of 25 or higher. (BMI = weight in kilograms divided by height in meters squared [kg/m²].) Overweight is defined as a BMI of 25 to 29.9, obesity as a BMI of 30 or higher. While most overweight or obese adults can lose weight by eating a healthy diet or increasing physical activity, doing both is most effective. See the Weight Management Guideline for recommendations and further information.
Contraception and preconception counseling
Preconception counseling should be provided to all female diabetic patients of childbearing age, as the risk of maternal-fetal complications is higher in the setting of uncontrolled blood glucose. Patients desiring conception should achieve an HbA1c < 6.5% prior to pregnancy. If a patient does not wish to conceive or is not at HbA1c target, contraception should be discussed. For more information, refer to the CDC U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.

Bariatric surgery
There is evidence that surgically induced weight loss results in better blood glucose control and less need for diabetic medications than conventional diabetes therapy focused on weight loss through lifestyle changes. Evidence from a large cohort study suggests that failure to sustain blood glucose control is an adverse predictor of diabetes relapse after surgery (Arterburn 2013). See the Bariatric Surgery Quick Care Guide and Clinical Review Criteria: Bariatric Surgery.

Pharmacologic options for glucose control

Metformin
Metformin should be titrated as tolerated. A reasonable initial titration schedule is:
- 500 mg ½ tab once daily X 7 days;
- 500 mg 1 tab once daily X 7 days;
- 500 mg 1 tab twice daily.

This initial titration schedule is now the default in KP HealthConnect. It provides 39 tablets, which equates to a true 30-day supply.

If a patient does not experience any GI side effects after 2–3 days, the dose may be titrated to goal of 1000 mg twice daily more quickly. (The maximum dose is 2000 mg/day).

If a patient develops GI side effects, reduce the dose and reassess. Consider a more conservative titration schedule starting with 500 mg ¼ tab (125 mg) orally once daily; alternatively, consider prescribing the XL formulation for patients who cannot tolerate the dose with regular-release formulation.

Precautions with metformin prescribing:
- **Monitor serum creatinine levels** because the medication is primarily excreted by the kidneys (see Table 6).
- **Reduce metformin dose** to a maximum of 500 mg twice daily in patients with eGFR 30–45.
- **Discontinue metformin dose** in patients with eGFR < 30, or whose eGFR has worsened by 25% or more since the previous reading.
- **Avoid use of metformin** in patients with known binge or excessive alcohol use. Instruct patients to avoid excessive acute or chronic alcohol use.
- **Suspend use of metformin** if a patient is to undergo a surgical procedure or be given iodinated contrast media for a radiological procedure, or has any severe illness. Restart metformin when normal renal function is verified or when severe illness resolves.
- **Metformin should be withheld** in patients with dehydration and/or prerenal azotemia.

Sulfonylureas
- **Glimepiride** remains the preferred sulfonylurea for those aged < 65 years; however, it has been added to the Beers list for drugs to avoid in the elderly. Glimepiride is primarily metabolized by the liver, with renal excretion of active metabolites.

A reasonable titration schedule for glimepiride is:
- Increase to 2 mg once daily for 1–2 weeks;
- Increase by 2 mg once daily at 1- to 2-week intervals to maximum of 8 mg once daily.

- **Glipizide** is the preferred sulfonylurea for those aged ≥ 65 years (for kidney toxicity avoidance to avoid excessive prolonged hypoglycemia). Glipizide is metabolized by the liver and primarily excreted in the urine as inactive metabolites, although one of its metabolites may have weak hypoglycemic activity.
A reasonable titration schedule for glipizide is:
Adults < 65 years: Starting dose 5 mg daily prior to morning meal. May move to twice-daily
dosing and increase based on before-meal response to maximum dose of 40 mg daily.
Elderly ≥ 65 years: Starting dose 2.5 mg daily prior to morning meal. May move to twice-daily
dosing and increase based on before-meal response to maximum dose of 20 mg daily. (If
CrCl < 50, reduce dose by 50%.)

Consider prescribing the extended-release formulation of glipizide for patients who cannot tolerate the
regular-release formulation. The most common side effect of sulfonylureas is hypoglycemia. Initiate
and titrate with caution in those with chronic kidney disease.

Titration schedule for extended-release products:
Adults < 65 years: Start 5–10 mg daily. Maximum dose is 20 mg daily.
Elderly ≥ 65 years: 2.5–5 mg daily. Maximum dose is 10 mg daily.

NPH insulin
Check fasting blood glucose (FBG) every day and get weekly average. The target is mean FBG of 80–
130 mg/dL. For adults over age 65, a higher target (140 mg/dL) may be considered. For a new start, use
the Insulin SmartRx in KP HealthConnect to choose the syringe or pen needles as well as testing
supplies (glucometer start kit, strips, lancets, and sharps container) if desired.

Weight-based dosing strategy:
- Start with 0.2 units/kg once daily at bedtime and adjust by 4–10 units per week.
- Reassess fasting and daytime BG once a dose of 0.6 units/kg of NPH is achieved.

Note: If insulin is over 0.6 units/kg, evaluate the need for daytime basal or mealtime insulin.

Treat-to-target strategy:
- Initial dose of 10 units basal insulin at bedtime.
- If FBG is higher than 130 mg/dL, increase bedtime insulin dose by 1 unit.
- If FBG is higher than 180 mg/dL, increase bedtime insulin dose by 2 units.
- Continue increasing bedtime insulin dose by 1–2 units at a time until FBG is in the target range.
- If FBG is lower than 80 mg/dL, decrease bedtime insulin dose by 2 units.
- If FBG is 50–70 mg/dL, decrease bedtime insulin dose by 4 units.
- Continue decreasing bedtime insulin dose by 2–4 units at a time until FBG is in the target range.
- Insulin 70/30 can be a cost-effective option when the need to intensify and eating patterns
support safe use.

If HbA1c is higher than 7.0% and blood glucose checks before lunch, dinner, and bedtime are indicating a
steady rise in blood glucose throughout the day, the patient very likely needs daytime insulin therapy.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Empagliflozin (Jardiance) is formulary. While the PA criteria was removed in March 2023, patients may still have a cost share. Use of half-tablet empagliflozin 25 mg daily instead of 10 mg tablets helps to reduce patient costs and avoid coverage gaps.

SGLT-2 inhibitors are recommended for patients with type 2 diabetes who meet the following Pharmacy criteria:

<table>
<thead>
<tr>
<th>Empagliflozin (Jardiance) Pharmacy criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients with type 2 diabetes:</td>
</tr>
<tr>
<td>• Currently on maximum tolerated dose of metformin (or contraindication, intolerance, or failure of maximum dose of metformin) with</td>
</tr>
<tr>
<td>o History of clinical atherosclerotic cardiovascular disease (ASCVD), heart failure, eGFR 20–59 or albuminuria (urine albumin/creatinine &gt; 30), or</td>
</tr>
<tr>
<td>o Age ≥ 55 years plus two or more of the following: hypertension (on medication), obesity (BMI ≥ 30), or dyslipidemia</td>
</tr>
<tr>
<td>-OR-</td>
</tr>
<tr>
<td>• Within 2% HbA1c goal with either failure, contraindication, or intolerance of maximum tolerated dose of metformin</td>
</tr>
<tr>
<td>-OR-</td>
</tr>
<tr>
<td>• At ≥ 2% of HbA1c goal with either failure, contraindication, or intolerance of maximum tolerated dose of metformin, and insulin*</td>
</tr>
<tr>
<td>*Note: Previously documented severe hypoglycemia would be considered an intolerance or contraindication to insulin therapy. Severe hypoglycemia includes hypoglycemia resulting in seizures, loss of consciousness, or needing help from others.</td>
</tr>
</tbody>
</table>

Precautions with SGLT-2 inhibitor prescribing:

• Avoid SGLT-2 inhibitor use in people with low intake of carbohydrates, such as a ketogenic dietary approach, as this may increase the risk for euglycemia ketoacidosis.
• SGLT-2 inhibitors are contraindicated in the context of heavy alcohol use. If aware of excess alcohol intake, stop the SGLT-2 inhibitor and reassess at a later date.
• Hold SGLT-2 inhibitors if there is an active lower limb infection, an illness that may result in dehydration (e.g., vomiting or diarrhea), or an active urinary tract infection (UTI), or if it is 3 days prior to procedures requiring patients to be NPO or have reduced dietary intake.

Ertugliflozin and canagliflozin in any combination with other diabetes agents are not recommended and remain non-formulary. While dapagliflozin also remains non-formulary, it is the preferred alternative for patients with a contraindication, intolerance, or failure of empagliflozin.
Non-formulary oral options that can be considered in patients at high hypoglycemia risk where cost is an issue

- **Acarbose**: alpha-glucosidase inhibitor (generic available)
  May have some cardiovascular benefit in those with impaired glucose tolerance. Generic, low risk of hypoglycemia.
  - Start 25 mg t.i.d. with first bite of food, can increase up to 100 mg t.i.d.
  - Predominant side effects include flatulence and diarrhea, which lead to low adherence in most patients.
- **Pioglitazone**: thiazoladinedione (generic available)
  Generic, non-formulary agent, low risk of hypoglycemia.
  - Start with 15 mg daily, increase up to 30 mg daily.
  - Significant side effects include weight gain, edema, increased risk of congestive heart failure. Contraindicated in patients with active liver disease.
  - Other concerns include increased risk of bone loss and osteoporotic fracture in women, and a potential increase in the risk of bladder cancer.

**Concentrated insulin**

Consider concentrated insulin for patients who are very insulin resistant and need more than 200 units of insulin per day or who are having unresolved hypoglycemia using glargine. Consultation with the Diabetes Team is not required before switching to U-500 insulin. **Note**: Several other concentrated insulin formulations exist (e.g., U-200, U-300) but are currently non-formulary. As of June 2023, formulary status is under evaluation.

**Other insulins for when cost is an issue**

Insulin 70/30 (NPH/REG)
- Twice-daily dose when need to intensify treatment and meal/eating patterns support use.
- If eating patterns are consistent—balanced with 2 or more meals daily—this can be a cost savings option.
Type 2 diabetes treatment algorithm

Consider:
- Acarbose,
- SU (contraindicated if high risk of severe hypoglycemia),
- TZD (contraindicated in heart failure),
- DDP-4 inhibitor, and/or
- Insulin

Metformin*

ASCVD?

YES

Consider adding
SGLT-2 inhibitor if eGFR >20.**

NO

Heart failure or eGFR 20–59?

YES

Consider adding SGLT-2 inhibitor **

NO

≥ 55 years plus at least 2:
HTN (on meds), BMI ≥ 30, dyslipidemia

NO

Add insulin

YES

HbA1c ≥ 2% above goal?

NO

BMI ≥ 30?

YES

Consider adding GLP-1 agonist (contraindicated in persistent gastroparesis)

NO

Consider adding SGLT-2 inhibitor if eGFR >20.**

* Do not start metformin if eGFR < 45. OK to continue max dose (1,000 mg/day) if eGFR 30–45.

** If eGFR <20 and considering SGLT-2 inhibitor, E-Consult Diabetes Team.
Type 2 diabetes treatment: when to consider glargine or U-500 insulin

Consider switch to glargine (Lantus). Decrease total daily dose (TDD) and titrate by 2-10 units/week to FBG target of 80-130 mg/dL.

SmartPhrase: DMLANTUSTITRATION
Initiation and titration orders

Continue to titrate standard insulin doses until HbA1c in target or patient is taking ≥200 units TDD.

Medicare patients will likely pay significantly more during the donut hole and should be advised or have a plan for management during that time frame.

Continue current regimen and monitor per guidelines.

Consider change/switch to Humulin R U-500 insulin.
BID dosing: BG checks before breakfast and dinner.
TID dosing: BG checks before meals (TID dosing may be recommended if taking >300 units/daily).

SmartPhrase: DMUS500TITRATION
Prescriber parameters for RN to convert patient to U-500 insulin

Reduce dose of U-500 by 10-20%. The injection volume is much less and absorption is improved, therefore a reduced dose decreases the risk for hypoglycemia.

If BG within 50 points of target, adjust by 5 units; if more than 50 from target, adjust by 10 units.

Virtual consult to Diabetes Team.

Continue current regimen and monitor per guidelines.

SmartPhrase: DMDAYTIMEINSULIN
Initiation and titration orders

Testing before and 2 hours after the main meal may give useful info about need for additional daytime insulin or sulfonylureas.

Medicare patients will likely pay significantly more during the donut hole and should be advised or have a plan for management during that time frame.

Humulin R U-100 may be more affordable for some insurance plans.

If patient is taking more than 1 unit/kg of basal insulin, consider adding mealtime insulin with largest meal of the day.

Continue to titrate Humulin N (NPH) insulin to target BG values (see previous page).

A1C goal met?

YES

Continue current regimen and monitor per guidelines.

Virtual consult to Diabetes Team.

NO

Add Humalog (lispro) or Humulin R U-100 with meal(s).
- or -
Add AM Humulin N (NPH).
- or -
Add glimepiride (see previous page).

A1C goal met?

YES

Continue current regimen and monitor per guidelines.

NO

Virtual consult to Diabetes Team.
Additional pharmacologic options to consider in consultation with the Diabetes Team

**Insulin glargine**
Glargine (Lantus) insulin offers no significant advantage over NPH insulin when given at bedtime to reduce fasting hyperglycemia and is considerably more expensive. For patients with type 2 diabetes who need intensive insulin schedules (which typically include both basal insulin and pre-meal boluses of rapid-acting insulin) or who experience recurrent hypoglycemia with NPH, glargine can be considered, similar to the way we manage patients with type 1 diabetes (see “Recommended physiologic insulin replacement schedule” in the Type 1 Diabetes Treatment Guideline).

**Glucagon-like peptide-1 (GLP-1) receptor agonists**
Liraglutide (Victoza) and semaglutide (Ozempic), which are formulary with PA, are used as adjuncts to diet and exercise to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established ASCVD. E-Consult with the Diabetes Team is suggested. Contraindicated in those with gastroparesis. Other GLP-1s, such as tirzepatide, are non-formulary, non-preferred agents at this time.

Liraglutide is a daily injection and semaglutide is a weekly injection.

**Pharmacy criteria for liraglutide and semaglutide**
For patients with type 2 diabetes:
- Currently on maximum tolerated dose of metformin (or contraindication, intolerance, or failure of maximum tolerated doses of metformin), and **contraindication, intolerance, or failure of an SGLT-2 inhibitor** (empagliflozin preferred) after a trial of at least 3 months duration, with
  - History of clinical atherosclerotic cardiovascular disease (ASCVD), or
  - Age ≥ 55 years plus two or more of the following: hypertension (on medication), obesity (BMI ≥ 30), or dyslipidemia
- OR-
- With hemoglobin A1c (HbA1c) within 2% of A1c goal and all of the following:
  - Clinically significant weight gain while on insulin therapy or BMI ≥ 30 prior to insulin therapy
  - Contraindication, failure, or intolerance to maximum tolerated dose of metformin
  - **Contraindication, failure, or intolerance, to achieve A1c goal with an SGLT-2 inhibitor** (empagliflozin preferred) after trial of at least 3 months duration
- OR-
- Contraindication, failure, or intolerance of maximum tolerated doses of metformin, insulin,* and an SGLT-2 **inhibitor** (empagliflozin preferred)

*Note: Previously documented severe hypoglycemia would be considered an intolerance or contraindication to insulin therapy. Severe hypoglycemia includes hypoglycemia resulting in seizures, loss of consciousness, or needing help from others.

**Continuous subcutaneous insulin infusion (insulin pumps or infusion pods)**
There is evidence to support the use of insulin pumps for a subset of patients with type 2 diabetes.

Motivated patients with type 2 diabetes who are having difficulty controlling their blood glucose with conventional intensive insulin regimens may be considered for insulin pumps. For more information, see Clinical Review Criteria: Insulin Pump. Patients with Medicare coverage must meet both the clinical review criteria and Medicare requirements to acquire and maintain use of a pump. The Omnipod system is the preferred insulin pump for new starts.

Note that the Diabetes Team sees patients with diabetes who are using or considering insulin pumps. The Insulin Pump Program can provide device training and consultation, at which time a care plan can be established to assist Primary Care with ongoing management. Primary Care retains responsibility for those patients’ overall diabetes plans of care and annual reviews of care.
Continuous glucose monitoring (CGM) systems

CGM systems allow the patient to get real-time blood glucose readings automatically. Data is transmitted to a receiver, which can be a Smart Phone, a handheld device called a reader (for Libre devices), or a handheld receiver (for Dexcom CGMs). See Summary of CGM Criteria for Initial Coverage (SharePoint).

Pharmacologic options that are not recommended

The following pharmacologic options are not recommended or not on the formulary; consider consultation with the Diabetes Team:

- Meglitinides—repaglinide (Prandin), nateglinide (Starlix)
- Amylinomimetics—pramlintide (Symlin)
- Dopamine agonists—bromocriptine (Cycloset)
- Bile acid sequestrants—colesevelam

There is no high-quality evidence to determine the effect on blood glucose control of any of the following:

- Chromium
- Cinnamon
- Vanadium
Chronic Disease Management Support

Chronic disease management (CDM) is a population health improvement program offered to KPWA members by nursing and pharmacy services. The program’s goal is to promote evidence-based practice and improve health care outcomes. Patients work with a registered nurse (RN) or clinical pharmacist (CP) for an average of 3–6 months to gain better control of their chronic disease.

*Note:* Beginning in Q3 2023, the CDM team will contact providers to authorize referral to Chronic Disease Management support for patients who meet the regional registry criteria that will be in place at that time.

<table>
<thead>
<tr>
<th>Table 3. Referral to Nursing or Clinical Pharmacy for chronic disease management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RN referral</strong></td>
</tr>
</tbody>
</table>
| **Patient characteristics** | **Type 1 or type 2 diabetes not at goal (A1c >8%)**<sup>2</sup>  
Agrees to work with RN | **Type 2 diabetes not at goal (A1c >8%)**<sup>2</sup> who also require active management for  
- Hypertension and/or  
- ASCVD prevention (e.g., lipid management)  
Agrees to work with CP |
| **Frequency of MD contact** | **Receipt of referral**  
If consult required  
At care transfer  
Other frequency per MD request |
| At initiation to establish treatment parameters  
As needed for changes to treatment plan  
At discharge | Referral will authorize RN to practice under the Type 1 and Type 2 Nursing Diabetes Medication Management standing orders (links follow table) for titration of insulin and oral medication. |
| Referral will authorize CP to practice under the collaborative drug therapy agreement (CDTA) for medication management. For more information about CDTAs and covered medication classes, see [Chronic Disease Management Support: Clinical Pharmacy](#). |
| **Nutrition counseling** | **Basic nutrition counseling provided; CP pends referral for medical nutrition therapy (MNT) to primary care provider as appropriate.** |
| Basic nutrition counseling provided; RN pends referral for medical nutrition therapy (MNT) to primary care provider as appropriate. | CP provides education regarding testing frequency, pattern recognition and interpretation. |
| **Glucose monitoring education** | | |
| RN provides device instruction if not provided at time of dispense.  
RN provides education regarding testing frequency, pattern recognition and interpretation. | CP provides education regarding testing frequency, pattern recognition and interpretation. |
| **Referral name** | **REF Clinical Nursing Services: CDM**  
**REF Clinical Pharmacy Services: CDM** |

<sup>1</sup> Newly diagnosed patients already at goal may be offered a teaching visit with clinic RN (CDM referral not required).

<sup>2</sup> Patients referred with HbA1c below 8.0% will be evaluated by the RN and CP to determine if there is a legitimate need for case management services versus a brief consult or single contact. CDM referral is not appropriate for self-management and/or nutrition education when HbA1c is at goal.
Follow-up and Monitoring

Self blood glucose monitoring

Table 4. Self blood glucose monitoring (SBGM)
Note that for patients with diabetes, SBGM is useful only if they are testing and using the information to make changes to their diabetes self-management plans.

<table>
<thead>
<tr>
<th>Eligible population</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients on lifestyle changes and/or metformin only</td>
<td>• These patients are not at risk for hypoglycemia.¹ It is reasonable for them not to do SBGM.</td>
</tr>
<tr>
<td></td>
<td>• Changes to therapy can be made based on HbA1c values every 3 months.</td>
</tr>
<tr>
<td></td>
<td>• Some patients may find that SBGM helps them see the effect of particular food items or exercise on their blood glucose, thus helping them stay motivated with lifestyle changes.</td>
</tr>
<tr>
<td>Patients on sulfonylureas and/or insulin</td>
<td>• These patients may develop hypoglycemia. It is advisable that they do SBGM when they “feel funny” to confirm whether or not their symptoms are due to hypoglycemia.</td>
</tr>
<tr>
<td></td>
<td>• If patients are using treat-to-target approaches, especially if using insulin (for example, titrating their dose of bedtime NPH insulin until they reach a fasting blood glucose target of 120 mg/dL), then testing the fasting blood glucose (FBG) once a day is advisable.</td>
</tr>
<tr>
<td></td>
<td>o Once patients achieve their FBG target, there is no need to continue testing every morning if they feel well and their HbA1c stays below their target range.</td>
</tr>
<tr>
<td></td>
<td>o However, if such patients are at their FBG target but their HbA1c is still above target, then testing before and 2 hours after their main meal may give useful information about the need for additional daytime treatment (with sulfonylurea or insulin).</td>
</tr>
<tr>
<td>Patients on basal insulin and pre-meal rapid-acting insulin</td>
<td>• These patients should do SBGM 3–4 times daily if they are using the information to adjust how much rapid-acting insulin they take before the meal.</td>
</tr>
<tr>
<td></td>
<td>• They may also want to test 2 hours after their main meal or under other circumstances where they want to know the effect of food, exercise, or stress on their blood glucose levels.</td>
</tr>
</tbody>
</table>

¹ Several studies have shown that improvement in HbA1c is almost identical whether patients test their blood glucose or not (Poolsup 2009).
Periodic monitoring of medication effectiveness and adverse effects

### Table 5. Monitoring for medication effectiveness and adverse effects

<table>
<thead>
<tr>
<th>Eligible population</th>
<th>Test</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effectiveness</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients being treated with GLP-1 receptor agonists</td>
<td>Weight</td>
<td>At 3 months, ensure at least 5% weight reduction and at least 0.5% HbA1c reduction.</td>
</tr>
<tr>
<td><strong>Adverse effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients being treated with metformin</td>
<td>Serum creatinine/eGFR</td>
<td>Annually if eGFR is 60 or lower or Twice a year if eGFR is 45 or lower.</td>
</tr>
<tr>
<td>Patients being treated with metformin with neuropathy or anemia</td>
<td>Vitamin B12</td>
<td>Every 2 years.</td>
</tr>
<tr>
<td>Patients being treated with SGLT-2 inhibitors</td>
<td>Estimated glomerular filtration rate (eGFR)</td>
<td>Monitor at baseline and at 3 months and 6 months after starting therapy.</td>
</tr>
</tbody>
</table>
Periodic monitoring of conditions and complications

<table>
<thead>
<tr>
<th>Condition/complication</th>
<th>Tests</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated blood pressure</td>
<td>BP taken with appropriate size cuff using optimal technique</td>
<td>Every visit.</td>
</tr>
<tr>
<td>Blood glucose control</td>
<td>HbA1c</td>
<td>Every 3 months until the target level is reached; thereafter, patients should be monitored at least every 6 months.</td>
</tr>
<tr>
<td>Foot ulcers</td>
<td>Physical exam focused on ankle reflexes, dorsalis pedis pulse, vibratory sensation, and 5.07 monofilament touch sensation performed by a provider qualified to determine the level of risk for foot ulcers</td>
<td>All patients with type 2 diabetes should have a documented foot exam at least annually. See Tip Sheet. Those at <strong>increased or very high risk</strong> (^2) should be assessed at every in-person visit.</td>
</tr>
<tr>
<td>Kidney health</td>
<td>Microalbumin/creatinine ratio (^1) and Estimated glomerular filtration rate (eGFR)</td>
<td>At least annually</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>Dilated eye exam by a trained eye services professional or Nondilated digital photography followed by a comprehensive exam for those who test positive</td>
<td>Patients <strong>with</strong> evidence of retinopathy should be screened annually. Patients <strong>without</strong> evidence of retinopathy should be screened every 2 years. (^3)</td>
</tr>
<tr>
<td>Electrolyte and chemistry abnormalities</td>
<td>Serum creatinine and Serum potassium</td>
<td>At least annually</td>
</tr>
<tr>
<td>Lipohypertrophy and lipodystrophy (^4)</td>
<td>Examine insulin injection sites or infusion set insertion sites.</td>
<td>At initial visit and at least annually</td>
</tr>
</tbody>
</table>

\(^1\) The microalbumin/creatinine ratio test can identify patients with microalbuminuria by giving a quantitative estimate of protein loss that correlates with 24-hour urinary protein measurements. Test results are expressed in micrograms of urinary albumin per milligram of urinary creatinine (or A:C ratio). A positive test is more than 30 mcg/mg. Two positive tests, ideally 3–6 months apart, are diagnostic for microalbuminuria.

\(^2\) See “Foot care” in the “Lifestyle modifications and non-pharmacologic options” section for foot-ulcer risk definitions.

\(^3\) Annual screening is not recommended because the benefits of more frequent screening are marginal: For every 1,000 persons screened annually (instead of every second year), one additional case of proliferative diabetic retinopathy and one additional case of clinically significant macular edema will be detected.

\(^4\) Lipohypertrophy and lipodystrophy can interfere with efficient insulin absorption.
Recommended immunizations

<table>
<thead>
<tr>
<th>Immunization</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>• Annually by the end of October</td>
</tr>
<tr>
<td></td>
<td>• Injectable vaccine recommended. Avoid LAIV (FluMist).</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td>• Patients aged 19 years and older who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV-20 or PCV-15). When PCV-15 is used, it should be followed by a dose of PPSV-23.</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>• Three-dose series for ages 19–59 years</td>
</tr>
<tr>
<td></td>
<td>• Age 60 years and older, depending on risk</td>
</tr>
</tbody>
</table>

| All other adult immunizations        | Per [CDC Recommended Adult Immunization Schedule by Medical Condition and Other Indications (2022)] |

Comorbidities

Depression screening

Screen for depression using the [Annual Mental Health Questionnaire](#). Evidence suggests that patients with depression are less likely to be adherent to recommended management plans and less likely to be effective at self-management of diabetes.

See the [Depression Guideline](#) for additional guidance. Patients with major depression can be treated in Primary Care or offered a referral to Mental Health and Wellness for counseling and/or drug therapy.

ASCVD prevention

Risk-reduction measures to consider include smoking cessation, blood pressure control, statin therapy, ACE inhibitor or angiotensin receptor blocker (ARB) therapy, and antiplatelet therapy.

ACE inhibitor or ARB therapy should be included for:

- Patients with type 1 or type 2 diabetes who have hypertension (BP > 140/90 mm Hg).
- Patients with type 2 diabetes aged 55 or older who have elevated microalbumin to creatinine ratio and additional cardiovascular risk factors.

See the ASCVD [primary prevention](#) and [secondary prevention](#) guidelines for details.

Blood pressure management

- The target is to treat all adults—including those with diabetes—to a blood pressure of below 140/90 mm Hg. How far below 140/90 mm Hg depends on the patient's clinical circumstances and overall ASCVD risk.
- **The target for adults with diabetes has changed from below 130/80 mm Hg to below 140/90 mm Hg.** Diabetes alone does not qualify a patient for a systolic blood pressure goal of less than 130 mm Hg.
- A systolic blood pressure goal of 130 mm Hg or lower is recommended for adults who:
  - Have 10-year ASCVD risk of 10% or higher
  - Have chronic kidney disease
  - Are age 75 or older
Evidence Summary
To develop the Type 2 Diabetes Screening and Treatment Guideline, the KP Washington guideline team:

- Adapted recommendations from externally developed evidence-based guidelines
- Reviewed additional literature using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis

Externally developed guidelines adapted

KPWA evidence review, 2017
The last full KPWA evidence review for this guideline was completed in 2017; at that time, the guideline team reviewed evidence in the following areas:

- Cardiovascular outcomes and safety
- Insulin pump therapy
- Biosimilar insulins with basal insulins
- U-500 or U-300 and U-100 insulin
- Insulin degludec versus U-100 insulin
- Bariatric surgery and type 2 diabetes with obesity

The next full evidence review for this guideline is scheduled in 2023.

Interim update, 2022
Recommendations revised in the December 2022 interim guideline update are based on Pharmacy & Therapeutics Committee monographs (publication pending as of January 2023). Evidence from the 2017 full guideline review has been superseded by evidence in the following areas: GLP-1 receptor agonists (liraglutide and semaglutide [Ozempic]), and SGLT-2 inhibitors (empagliflozin and dapagliflozin).

Cardiovascular outcomes and safety

Glucagon-like peptide-1 (GLP-1) receptor agonists

One high-quality meta-analysis (Palmer 2016) of 301 trials involving 120,000 adults found no difference in all-cause mortality, myocardial infarction, and stroke between GLP-1 receptor agonists and other medications. Likewise, no significant difference was found in the risk of mortality due to cardiovascular events between any single or metformin-based combination therapies in the short term (6 months). In addition, no significant differences were reported for metformin-based combination therapies in terms of all-cause mortality, serious adverse events, MI, and stroke.

Low- to moderate-quality evidence (RCTs and meta-analyses) showed inconsistencies: Four studies (Ding 2016, Ferdinand 2016, Howse 2016, and Wang 2016) found no significant difference in major cardiovascular adverse events (cardiovascular mortality, non-fatal MI, non-fatal stroke) between GLP-1 receptor agonists and placebo or active comparators (RR: 0.99; 95% CI, 0.88–1.12; p=0.872 [Ding 2016]; (HR 0.57; adj. 98.02% CI, 0.30–1.10 [Ferdinand 2016]).

Two RCTs reported a statistically significant reduction in the risk of major cardiovascular adverse events between semaglutide and placebo (HR: 0.74; 95% CI, 0.58-0.95; p < 0.001 [Marso, Bain, et al 2016]) and between liraglutide and placebo (HR: 0.87 [0.78–0.97]; p < 0.001 [Marso, Daniels, et al 2016]).

DPP4 inhibitors (DPP4-i)

A systematic review (Mannucci 2017) on the cardiovascular safety of DPP4-inhibitors reported that DPP4-inhibitors were not associated with increased cardiovascular risk. However, a number of meta-analyses from this review suggested that results were inconsistent for the drugs as a class, as at least four meta-analyses showed that DPP4-inhibitors were significantly associated with a reduction in cardiovascular risk and at least four other studies reported no difference.
For individual drugs, the results were conflicting for saxagliptin and sitagliptin; vildagliptin significantly lowered major adverse cardiac event (MACE) risk; linagliptin significantly lowered the risk of stroke; alogliptin showed no difference in MACE risk. DPP4-i was assessed as monotherapy and as combination therapy with other antidiabetic medications.

Limitations: The number of events was small for statistical analysis. The definitions of MACE varied across studies; there were reliability issues and the post hoc design (except in studies that evaluated linagliptin and alogliptin) may have affected the results; the cardiovascular risk status of patients in some studies was lacking; the follow-up period was short (2 years), raising the concern of long-term outcomes (one study assessed 4 years outcomes); and the standard care that patients received might have affected the findings.

However, a statistically significant increased risk of MACE was not observed. The evidence is of low quality.

**SGLT-2 inhibitors**

Five meta-analyses of RCTs (Monami 2016, Palmer 2016, Sonesson 2016, Tang 2016, Su 2016) assessed the cardiovascular outcomes of SGLT-2 inhibitors. Although comparisons were made between SGLT-2 inhibitors and other antidiabetic agents, the main comparison was SGLT-2 inhibitor versus placebo. Canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin were assessed. Sample size ranged from 5,936 to 120,000 adults. Duration of diabetes was > 10 years; mean follow-up was < 2 years (but up to 5.4 years); some patients had established cardiovascular disease or history of CV disease and others did not. Patients had background treatment in most studies. Demographics and baseline characteristics were not different across groups. While most of the studies reported favorable CV outcomes and all-cause mortality for SGLT-2 inhibitors, the biggest meta-analysis concluded there was no difference in CV risk and all-cause mortality between SGLT-2 inhibitors and placebo or active controls. For non-fatal stroke, one meta-analysis reported that SGLT-2 inhibitors significantly increased the risk of stroke whereas another one reported no difference.

The EMPA-REG OUTCOME was a randomized, double-blind, Phase 3 trial that assessed the safety of empagliflozin compared to placebo for 7,020 patients with type 2 diabetes and established cardiovascular disease (Monami 2016). Empagliflozin has been shown to reduce CV and overall mortality when added to standard glucose-lowering agents (i.e., metformin, insulin, and sulfonylureas), and treatment with empagliflozin resulted in a 38% relative risk reduction (2.2% absolute risk reduction) in cardiovascular deaths. However, empagliflozin’s effect on MI is not significant and clinical benefit in the setting of primary prevention for CVD is still unknown.

Compared to each other, no statistically significant difference in CV outcomes among individual medications was reported. The most frequently reported adverse event was genital infection.

The main limitations were short follow-up, variability of study populations, and small number of events. Moderate- to high-quality evidence shows conflicting results on the risk of CV events and all-cause mortality in the short term (< 2 years).

**Thiazolidinediones (TZDs)**

Insufficient evidence precludes conclusions about the comparative effectiveness of TZDs on cardiovascular outcomes in adults with type 2 diabetes.

**Insulin pump therapy**

A randomized controlled trial (Aronson 2016) that enrolled 331 patients compared insulin pump therapy and multiple daily injections (MDI) in patients with type 2 diabetes. The authors reported that compared with multiple daily injections, pump therapy was more effective in reducing HbA1c and total daily insulin dose over 12 months in patients with type 2 diabetes. No major adverse events were reported. However, the results should be interpreted with caution, and the overall risk of bias is high. Precision of study: precise; directness: direct outcomes were assessed. Overall, the evidence is of moderate quality.
**Biosimilar insulins with basal insulins**

Two multinational RCTs (Blevins 2015, Rosenstock 2015) were critically appraised. The primary outcome was to demonstrate the non-inferiority of LY IGlar over IGlar (0.4% and 0.3% non-inferiority margin). Sample sizes ranged from 535 (all type 1 diabetes) to 756 (all type 2 diabetes) patients. Baseline characteristics were similar across groups in each study. The mean HbA1c was 7.7% and 8.3%, respectively, in the studies. In the study that looked at type 1 diabetes (Blevins 2015), patients were randomized to either LY IGlar once per day or IGlar once-daily with mealtime insulin lispro, whereas in the study that looked at type 2 diabetes (Rosenstock 2015), patients who were previously treated with IGlar or ≥ 2 oral antihyperglycemic drugs were randomized to either once-daily LY IGlar or IGlar. Patients were followed for 24 weeks for the primary outcome. However, the follow-up for safety was 52 weeks in one study (Blevins 2015). In both studies, HbA1c decreased in both groups from baseline to 24 weeks (even at 52 weeks), but the improvement was marked in patients receiving LY IGlar. This suggests that LY IGlar was non-inferior to IGlar on the change of HbA1c at both the 0.4 and 0.3% non-inferiority margins. However, the results were not statistically significant. In addition, there were no statistically significant differences in the following outcomes: proportions of patients achieving target HbA1c < 7%, fasting plasma glucose, self-monitored blood glucose, daily mean blood glucose, and basal insulin dose. Adverse events were similar; the most common were hypoglycemia, nasopharyngitis, upper respiratory tract infection, and diarrhea.

Moderate evidence shows no statistically significant difference in glucose control between LY IGlar (biosimilar insulin) and IGlar in patients with type 1 or type 2 diabetes.

**U-500 or U-300 and U-100 insulin**

There is no new evidence to suggest that more concentrated insulins (U-500 or U-300) in patients with type 2 diabetes with insulin resistance result in better glycemic control compared to U-100 insulin.

**Insulin degludec versus U-100 insulin**

Two meta-analyses (Einhorn 2015, Rodbard 2013), two RCTs (Kumar 2016, Onda 2016), and one retrospective study (Ghosal 2016) assessed the outcomes of IDeg in comparison to IGlar. The Einhorn meta-analysis investigated the effects of IDeg among patients who achieved good glycemic control, and the Rodbard meta-analysis assessed similar outcomes in patients requiring high insulin dose. The meta-analyses included 12 RCTs. One of the RCTs was a pilot study with insufficient power. Sample size was up to 3,000 patients and baseline characteristics were similar between groups. Patients were followed for ≤ 1 year. Some patients received concomitant oral agents including metformin, DPP-4I, pioglitazone, and SU. One study compared IDegAsp versus IGlar and another study compared IDeg followed by IGlar versus IGlar followed by IDeg.

Limitations included differences in populations, short follow-up periods, bias related to the open label design of some trials, and failure to specify the exact concentration of IGlar given to patients.

Moderate evidence shows conflicting results between IDeg and IGlar in terms of hypoglycemic events, fasting plasma glucose, and insulin dose. However, IDeg may lower nocturnal hypoglycemic incidence (moderate evidence). There is no statistically significant difference in HbA1c reduction between IDeg and IGlar (moderate evidence). In terms of cardiovascular effects, there is insufficient evidence to assess the cardiovascular outcomes of insulin degludec compared to U-100 insulin.

**Bariatric surgery and type 2 diabetes with obesity**

**Bariatric surgery versus medical treatment in type 2 diabetes patients with obesity**

Two meta-analyses (Rohde 2016, Yan 2016) and three RCTs were reviewed (Cummings 2016, Ding 2015, Schauer 2017). These compared bariatric surgery versus medical management in patients with type 2 diabetes who were obese. Bariatric surgery included laparoscopic adjustable gastric band (LAGB), RYGB, and duodenal-jejunal bypass sleeve (DJBS). Medical management included diet modifications; medications for controlling hyperglycemia, dyslipidemia, and hypertension; weight management; decreasing energy intake; and increasing physical activity.
Baseline characteristics were similar across studies. HbA1c ranged from 7.9 to 10.5%; BMI: > 27 kg/m² including morbid obesity; duration of diabetes was up to 13 years; age varied from 20 to 64 years; cardiovascular risk factors; follow-up ranged from 1 to 5 years; only one study (included in the meta-analysis) followed patients for 5 years; one RCT (Schauer 2017) also followed patients for 5 years. Diabetes-related complications were not marked.

RYGB or LAGB was found to be more effective than medical treatment in type 2 diabetes remission (one meta-analysis and 2 RCTs). RYGB or LAGB was more effective than medical management in reduction of cardiometabolic risk factors such as BMI, waist circumference, serum lipida, blood pressure, quality of life, and use of medications (although the very small sample size study reported no significant difference in quality of life). However, one RCT with small sample size found no statistically significant difference in cardiometabolic risk factors. No major adverse events were reported.

The major limitation was the duration of the trials, wherein an investigation of end-organ damage could not be performed.

Overall, moderate evidence shows that RYGB or LAGB is more effective than medical treatment in glycemic control, type 2 diabetes remission and reduction of cardiometabolic risk factors in the short to medium term (1–5 years). There is insufficient evidence for patients with BMI < 35 kg/m².

**Bariatric surgery versus medical treatment in type 2 diabetes patients with obesity on end-organ complications**

- Diabetic retinopathy: One RCT (Schauer 2017) and a number of non–randomized controlled studies (Abbatini 2013, Johnson 2013, Miras 2015, Zakaria 2016) reported conflicting evidence for the effects of bariatric surgery on diabetic retinopathy in the short term; in the long term, there is no statistically significant difference between surgery and medical treatment.
- Diabetic nephropathy: Based on one RCT (Schauer 2017) with moderate quality and a number of retrospective studies (Amor 2013, Brethauer 2013, Carlsson 2013, Iaconelli 2011, Johnson 2013), results are conflicting.
- Diabetic neuropathy: Evidence is limited; a firm conclusion cannot be made.
- Cardiovascular: Low to moderate evidence (Chen 2016, Ding 2015, Douglas 2015, Ricci 2015, Yan 2016) shows that bariatric surgery may decrease the risk of hypertension and macrovascular complications. More trials are warranted to determine the effects on stroke.

**References**


Development process
The Type 2 Diabetes Screening and Treatment Guideline was developed using an evidence-based process, including systematic literature search, critical appraisal, and evidence synthesis. For details, see Evidence Summary and References.

This edition of the guideline was approved for publication by the Guideline Oversight Group in March 2021.

Team (interim update May 2023)
The Type 2 Diabetes Screening and Treatment Guideline development team included representatives from the following specialties: endocrinology, nursing, and pharmacy.

Clinician lead: John Dunn, MD, MPH, Medical Director, Knowledge & Implementation
Guideline coordinator: Avra Cohen, MN, RN, Clinical Improvement & Prevention

Meredith Cotton, MSN, RN, CDCES, BC-ADM, Population Care Diabetes Program
Dan Kent, PharmD, CDCES, Clinical Specialty Program Coordinator
Wendy Robinson, MN, RN, CWCN, Manager, Population Care Diabetes Program
Ann Stedronsky, Clinical Publications, Clinical Improvement & Prevention
Melissa Sturgis, PharmD, BCACP, Pharmacy Clinical Programs Coordinator
Amber Sweeny, RN, MSN, CDCES, BC-ADM, Population Care Diabetes Program
Tiana Wright, MSN, RN-BC, Assistant Manager, Population Care Diabetes Program